DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,978 filers reported holding DANAHER CORPORATION in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $120,165,250 | +10.8% | 484,342 | +7.2% | 1.85% | +13.7% |
Q2 2023 | $108,411,840 | -4.3% | 451,716 | +0.5% | 1.62% | -8.5% |
Q1 2023 | $113,334,228 | -6.4% | 449,668 | -1.4% | 1.78% | -12.5% |
Q4 2022 | $121,104,664 | +1.4% | 456,276 | -1.3% | 2.03% | -2.5% |
Q3 2022 | $119,457,000 | +0.4% | 462,490 | -1.4% | 2.08% | +8.0% |
Q2 2022 | $118,959,000 | -13.9% | 469,228 | -0.3% | 1.92% | +0.1% |
Q1 2022 | $138,091,000 | -11.2% | 470,770 | -0.4% | 1.92% | -0.9% |
Q4 2021 | $155,469,000 | +7.9% | 472,536 | -0.1% | 1.94% | -3.6% |
Q3 2021 | $144,039,000 | +12.5% | 473,127 | -0.8% | 2.02% | +12.6% |
Q2 2021 | $127,998,000 | +18.2% | 476,963 | -0.9% | 1.79% | +5.7% |
Q1 2021 | $108,281,000 | +1.5% | 481,078 | +0.2% | 1.69% | -2.6% |
Q4 2020 | $106,659,000 | +2.5% | 480,145 | -0.7% | 1.74% | -9.7% |
Q3 2020 | $104,070,000 | +21.0% | 483,306 | -0.7% | 1.92% | +9.3% |
Q2 2020 | $86,024,000 | +28.1% | 486,480 | +0.2% | 1.76% | +0.5% |
Q1 2020 | $67,169,000 | -11.4% | 485,292 | -1.7% | 1.75% | +21.0% |
Q4 2019 | $75,791,000 | +5.9% | 493,820 | -0.3% | 1.45% | -1.2% |
Q3 2019 | $71,548,000 | – | 495,385 | – | 1.47% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |